+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cough Hypersensitivity Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

  • ID: 4911485
  • Report
  • November 2019
  • Region: Global
  • 167 pages
  • Transparency Market Research
1 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer, Inc.
  • MORE
Cough Hypersensitivity Syndrome Treatment Market - Scope of the Report

The report on the global cough hypersensitivity syndrome treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market, for the forecast period of 2019 to 2027. The report provides the overall revenue of the global cough hypersensitivity syndrome treatment market from 2017 to 2027, with 2018 as the base year and 2017 as the historical year. The report also provides the compound annual growth rate (CAGR) for the global cough hypersensitivity syndrome treatment market for the period of 2019 to 2027.

The report has been prepared after extensive primary and secondary research. Primary research involves bulk of the research efforts, wherein, analysts carry out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global cough hypersensitivity syndrome treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of the top-down and bottom-up approach to study various phenomena in the global cough hypersensitivity syndrome treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global cough hypersensitivity syndrome treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global cough hypersensitivity syndrome treatment market.

The report delves into the competitive landscape of the global cough hypersensitivity syndrome treatment market. Key players operating in the global cough hypersensitivity syndrome treatment market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overviews, financial standings, recent developments, and SWOTs are some of the attributes of players in the global cough hypersensitivity syndrome treatment market that have been profiled in this report.

Key Questions Answered in the Cough Hypersensitivity Syndrome Treatment Market Report
  • What is the revenue expected to be generated by cough hypersensitivity syndrome treatment for each drug class across all regions during the forecast period?
  • What are the opportunities in the global cough hypersensitivity syndrome treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the global cough hypersensitivity syndrome treatment market?
  • Which regional market is likely to expand at the maximum CAGR during the forecast period?
  • Which cough hypersensitivity syndrome treatment distribution channel is expected to generate the highest revenue, globally, in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What is the position of different companies operating in the global cough hypersensitivity syndrome treatment market?
Cough Hypersensitivity Syndrome Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global cough hypersensitivity syndrome treatment market begins with an overview of the said market, followed by the scope and objectives of this study. Following this, the report provides a detailed explanation of the objectives behind this study, and the pipeline analysis of different drugs in the treatment of cough hypersensitivity syndrome. This report also provides the epidemiological overview of the cough hypersensitivity syndrome, globally, and in main countries.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables, appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows the comparison of market shares of key segments in the past and at the end of the forecast period.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer, Inc.
  • MORE
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Cough Hypersensitivity Syndrome Treatment Market

4. Market Overview
4.1. Introduction
4.1.1. Respiratory Drug Classes Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Key Insights
5.1. Epidemiology Cough hypersensitivity syndrome
5.2. Pipeline Analysis

6. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Drug Class, 2017–2027
6.3.1. Antitussive Agents
6.3.2. Inhaled Corticosteroids (ICS)
6.3.3. Short Acting Beta2-Agonists (SABA)
6.3.4. Anti-cholinergics
6.3.5. Antihistamines
6.3.6. Proton Pump Inhibitors
6.3.7. Others
6.4. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Drug Class

7. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel

8. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Region
8.1. Key Findings
8.2. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Region

9. North America Cough Hypersensitivity Syndrome Treatment Market Value Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
9.2.1. Antitussive Agents
9.2.2. Inhaled Corticosteroids (ICS)
9.2.3. Short Acting Beta2-Agonists (SABA)
9.2.4. Anti-cholinergics
9.2.5. Antihistamines
9.2.6. Proton Pump Inhibitors
9.2.7. Others
9.3. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
10.2.1. Antitussive Agents
10.2.2. Inhaled corticosteroids (ICS)
10.2.3. Short-Acting Beta2-Agonists (SABA)
10.2.4. Anti-cholinergics
10.2.5. Antihistamines
10.2.6. Proton Pump Inhibitors
10.2.7. Others
10.3. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country

11. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
11.2.1. Antitussive Agents
11.2.2. Inhaled corticosteroids (ICS)
11.2.3. Short-Acting Beta2-Agonists (SABA)
11.2.4. Anti-cholinergics
11.2.5. Antihistamines
11.2.6. Proton Pump Inhibitors
11.2.7. Others
11.3. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
12.2.1. Antitussive Agents
12.2.2. Inhaled corticosteroids (ICS)
12.2.3. Short-Acting Beta2-Agonists (SABA)
12.2.4. Anti-cholinergics
12.2.5. Antihistamines
12.2.6. Proton Pump Inhibitors
12.2.7. Others
12.3. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
13.2.1. Antitussive Agents
13.2.2. Inhaled corticosteroids (ICS)
13.2.3. Short-Acting Beta2-Agonists (SABA)
13.2.4. Anti-cholinergics
13.2.5. Antihistamines
13.2.6. Proton Pump Inhibitors
13.2.7. Others
13.3. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027
13.4.1. GCC
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis by Company (2018)
14.3. Company Profiles
14.3.1. Pfizer, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. Strategic Overview
14.3.1.5. SWOT Analysis
14.3.2. GlaxoSmithKline plc
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. Strategic Overview
14.3.2.5. SWOT Analysis
14.3.3. Boehringer Ingelheim GmbH
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. Strategic Overview
14.3.3.5. SWOT Analysis
14.3.4. AstraZeneca
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. Strategic Overview
14.3.4.5. SWOT Analysis
14.3.5. F. Hoffmann-La Roche Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. Strategic Overview
14.3.5.5. SWOT Analysis
14.3.6. Teva Pharmaceutical Industries Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. Strategic Overview
14.3.6.5. SWOT Analysis
14.3.7. Novartis AG
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. Strategic Overview
14.3.7.5. SWOT Analysis
14.3.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp)
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. Strategic Overview
14.3.8.5. SWOT Analysis
14.3.9. Vertex Pharmaceuticals Incorporated
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. Strategic Overview
14.3.9.5. SWOT Analysis
14.3.10. Johnson & Johnson Consumer Inc.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. Strategic Overview
14.3.10.5. SWOT Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Boehringer Ingelheim GmbH
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp)
  • Vertex Pharmaceuticals Incorporated
  • Johnson & Johnson Consumer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll